claim: iga mab blocks sars-cov-2 spike-ace2 interaction providing mucosal immunity
evidence_1: sars-cov-2 specific iga antibodies, such as mab362, may provide effective immunity against sars- cov-2 by inducing mucosal immunity within the respiratory system, a potentially critical feature of an effective vaccine.